IMPRESS (algenpantucel-L)
The largest vaccine trial after pancreatic cancer surgery found that algenpantucel-L added nothing to standard chemotherapy.
Overview
IMPRESS enrolled 722 patients after resection of pancreatic adenocarcinoma and randomised them to standard adjuvant therapy with or without the whole-cell vaccine algenpantucel-L. Overall survival, the primary endpoint, was not improved, ending the hyperacute vaccine approach in this disease.
Setting
Resected pancreatic cancer: adjuvant gemcitabine with or without chemoradiation, with or without algenpantucel-L
Phase
Phase 3
Sponsor
NewLink Genetics
Registry
Headline result
No overall survival benefit.
Reported
2016
Similar pages
not linked directly; found by shared links- CompanyNewLink Genetics (now Lumos Pharma)
- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
- TrialANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- TrialSafety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer